Diabetes Drugs and Devices Market to Exceed USD 85 Billion by 2020 due Global Rise in Diabetic Population and Associated Diseases

According to a new market research report published by iHealthcareAnalyst, Inc., Diabetes Drugs and Devices Market – Global Diabetes Products Analysis and Forecast 2013-2023, the global diabetes drugs and devices market is estimated to exceed USD 85 Billion in 2020, expanding at a CAGR of 4.4% from 2016 to 2020.

Visit the Diabetes Drugs and Devices Market – Global Diabetes Products Analysis and Forecast 2013-2023 report at http://www.ihealthcareanalyst.com/report/diabetes-drugs-devices-market/

The type of diabetes determines either blood sugar monitoring, insulin or oral medications as a treatment. Treatment for type 1 diabetes involves insulin injections or the use of an insulin pump, frequent blood sugar checks, and carbohydrate counting. Treatment of type 2 diabetes primarily involves monitoring of your blood sugar, along with diabetes medications, insulin or both. The global diabetes drugs and devices market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (insulin derivatives - short-acting, intermediate-acting, long-acting, premixed, and rapid-acting insulin; oral anti-diabetes drugs - alpha-glucosidase inhibitors, biguanides, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylureas, thiazolidinediones; and non-insulin injectable anti-diabetes drugs – GLP-1 analogs), device type (diabetes monitoring and diagnostic devices - analog glucose meter, continuous glucose monitoring devices, glucose test strips, lancets and lancing devices; insulin delivery devices - insulin injectors, pens, pumps, syringes, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

The global diabetes drugs and devices market is segmented as:

1. Drug Type
1.1. Insulin
1.1.1. Short-Acting Insulin Derivatives
1.1.2. Intermediate-Acting Insulin Derivatives
1.1.3. Long-Acting Insulin Derivatives
1.1.4. Premixed Insulin Derivatives
1.1.5. Rapid-Acting Insulin Derivatives
1.2. Oral Anti-Diabetes Drugs (Drugs Class)
1.2.1. Alpha-Glucosidase Inhibitors
1.2.2. Biguanides
1.2.3. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
1.2.4. Meglitinides
1.2.5. Sodium/Glucose Cotransporter 2 (SGLT-2) Inhibitors
1.2.6. Sulphonylureas
1.2.7. Thiazolidinediones
1.3. Non-Insulin Injectable Anti-Diabetes Drugs
1.3.1. Glucagon-like peptide-1 (GLP-1) Analogs

2. Device Type
2.1. Diabetes Monitoring And Diagnostic Devices
2.1.1. Analog Glucose Meter
2.1.2. Continuous Glucose Monitoring Devices
2.1.3. Glucose Test Strips
2.1.4. Lancets And Lancing Devices
2.1.5. Others
2.2. Insulin Delivery Devices
2.2.1. Insulin Injectors
2.2.2. Insulin Pens
2.2.3. Insulin Pumps
2.2.4. Insulin Syringes

1. Geography (Region, Country)
1.1. North America (U.S., Canada)
1.2. Latin America (Brazil, Mexico, Rest of LA)
1.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
1.4. Asia Pacific (Japan, China, India, Rest of APAC)

3. Company Profiles
3.1. Abbott Laboratories, Inc.
3.2. AstraZeneca plc
3.3. B. Braun Melsungen AG
3.4. Bayer HealthCare AG
3.5. Becton, Dickinson & Company
3.6. Boehringer Ingelheim GmbH
3.7. DexCom, Inc.
3.8. Eli Lilly and Company
3.9. F. Hoffmann-La Roche Ltd.
3.10. GlaxoSmithKline plc
3.11. Johnson & Johnson
3.12. Lupin Limited
3.13. Medtronic, Inc.
3.14. Merck & Co., Inc.
3.15. Novartis International AG
3.16. Novo Nordisk A/S
3.17. Sanofi
3.18. Takeda Pharmaceuticals

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
http://www.ihealthcareanalyst.com

This release was published on openPR.